SLITRK5 is a cellular protein whose normal function appears to suppress bone formation and could be a potential new target for the treatment ofosteoporosis, according to a collaborative study conducted by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Cells manifesting the SLITRK5 protein are marked with magenta (left) and a bone-forming osteoblast marker in green (center). These markers were observed in the cancellous bone in the medulla space (top) or on the outer layer covering the bone (bottom). The overlap between these two markers (right) shows that SLITRK5 is found in bone-forming osteoblasts but not in other cell types, helping to make SLITRK5 a target for skeletal disease treatment. Credit: Dr. Matthew Greenblatt and Dr. Jun Sun
There Research was published in the scientific journal Nature Communications.
Read Also
- A British expert explained why Putin is headed for a “catastrophic failure” and will lose the war in Ukraine May 30, 2022
- Green pass Italy, Vaia: “Yes to an extension even beyond a year” Aug 26, 2021
- Electronic nose “feels” when lung transplant fails Sep 9, 2021
- Suakai in Aledo. Quality culture in remote enclaves of Spain Aug 11, 2021
- SEHA launches “WhatsApp” service to book vaccine appointments and answer inquiries Aug 21, 2021
- Jul explains her silence on social networks… Kate honors Lady Di for her first Princess of Wales dinner… Nov 24, 2022
- La France insoumise: first political council, without Ruffin, Autain, Corbière or Garrido Jan 16, 2023